Frontlight ResearchEarly access
CompletedNo phase
Host Dysregulation-Driven Sepsis Prediction Model
Key facts
- Who runs it
- Second Affiliated Hospital of Wenzhou Medical University
- Where
- China2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 1,000 people enrolled
- Started
- 1 Sept 2024
- Ended
- 17 Oct 2024
- Type of study
- Observational, 2 groups
- Treatments tested
- Tumor Necrosis Factor
- Interleukin-1β
- Interleukin-12
- Interleukin-18
- Complement C3
- Complement C5
- Record updated
- 31 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients with Infection or Suspected Infection
Who cannot take part
- Patients with Autoimmune Diseases
- Patients with Advanced-Stage Cancer and Systemic Metastasis
- Pregnant Women
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to identify risk factors associated with sepsis and to construct a predictive model for sepsis. This will provide an objective theoretical and empirical foundation for the diagnosis, assessment, and management of sepsis in our country.The primary questions addressed are:
Read full original descriptionShow less
What are the risk factors for the development of sepsis? How do we improve the prognosis of sepsis?
The 2 groups in the trial
- Sepsis Group
Treatment: Tumor Necrosis Factor, Interleukin-1β, Interleukin-12, Interleukin-18, Complement C3, and Complement C5
- Non-Sepsis Group
Treatment: Tumor Necrosis Factor, Interleukin-1β, Interleukin-12, Interleukin-18, Complement C3, and Complement C5
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Construction and Validation of a Sepsis Prediction Model Based on Dysregulation of Host Response
- Record updated
- 31 October 2024